← All trials
NCT07212868
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2025
- Primary completion
- May 1, 2030
- Completion date
- Jun 30, 2030
- First posted
- Oct 8, 2025
- Last posted
- Nov 12, 2025
- Enrollment
- 150
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Texas, San AntonioLead sponsor
- University of Texas, San AntonioSponsor investigator
- University of Texas, San AntonioOfficial
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Collaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.